For research use only. Not for therapeutic Use.
ZLN005-d4 (CAS: 2410443-42-2), a premium pharmaceutical research compound designed for advanced metabolic and diabetes studies. As a deuterated analog of ZLN005, it offers enhanced stability and improved pharmacokinetic properties. ZLN005-d4 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for metabolic disorders and diabetes. Trusted by leading laboratories, ZLN005-d4 is your go-to solution for cutting-edge metabolic research. Unlock new possibilities in diabetes treatment with ZLN005-d4, where innovation meets reliability.
| Catalog Number | S000142 |
| CAS Number | 2410443-42-2 |
| Molecular Formula | C17H14D4N2 |
| Purity | ≥95% |
| Target | Autophagy |
| IUPAC Name | 2-(4-tert-butylphenyl)-4,5,6,7-tetradeuterio-1H-benzimidazole |
| InChI | InChI=1S/C17H18N2/c1-17(2,3)13-10-8-12(9-11-13)16-18-14-6-4-5-7-15(14)19-16/h4-11H,1-3H3,(H,18,19)/i4D,5D,6D,7D |
| InChIKey | LQUNNCQSFFKSSK-UGWFXTGHSA-N |
| SMILES | [2H]C1=C(C(=C2C(=C1[2H])NC(=N2)C3=CC=C(C=C3)C(C)(C)C)[2H])[2H] |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Zhang LN, et al. Novel small-molecule PGC-1α transcriptional regulator with beneficial effects on diabetic db/db mice. Diabetes. 2013 Apr;62(4):1297-307. |
